There are 2137 resources available
671P - Prospective assessment of AR splice variant and PSMA detection on circulating tumour cells of mCRPC patients: Preliminary results of PRIMERA trial (NCT04188275)
Presenter: Giulio Francolini
Session: E-Poster Display
Resources:
Abstract
672P - Fracture risk in men with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra 223)
Presenter: Adham Hijab
Session: E-Poster Display
Resources:
Abstract
673P - Assessing bone health and osteoporotic risk in patients requiring anti androgen therapy for prostate cancer
Presenter: Nicola Hannaway
Session: E-Poster Display
Resources:
Abstract
674P - Evaluation of cognitive function (CogF) in trials testing new-generation hormonal treatments (NGHT) in patients with prostate cancer (PC): A systematic review
Presenter: Laura Marandino
Session: E-Poster Display
Resources:
Abstract
675P - HER2 expression in circulating tumour cells is associated with poor outcomes in patients with metastatic castration resistant prostate cancer
Presenter: Denis Maillet
Session: E-Poster Display
Resources:
Abstract
676P - Prognostic role of nutritional status (NS) for health-related quality of life (HRQoL) in men with advanced prostate cancer
Presenter: Luka Cavka
Session: E-Poster Display
Resources:
Abstract
677P - A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa): Final analysis
Presenter: Deepak Kilari
Session: E-Poster Display
Resources:
Abstract
678P - Metastasis-directed stereotactic body radiotherapy (SBRT)-guided by PET-CT 18F-choline versus PET-CT 68Ga-PSMA in castration sensitive oligorecurrent prostate cancer: A comparative effectiveness analysis
Presenter: Luca Nicosia
Session: E-Poster Display
Resources:
Abstract
679P - Treatment patterns of metastatic castration-sensitive prostate cancer (mCSPC): A real-world evidence study
Presenter: Scott Tagawa
Session: E-Poster Display
Resources:
Abstract
680P - Comparative efficacy of first-line novel anti-androgen therapies versus docetaxel in metastatic hormone sensitive prostate cancer (mHSPC): An updated network meta-analysis
Presenter: Philip Haddad
Session: E-Poster Display
Resources:
Abstract